InterCure (INCR) Competitors

InterCure (NASDAQ:INCR) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

Do insiders and institutionals believe in INCR or ALLO?

8.3% of InterCure shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 0.2% of InterCure shares are held by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Which has more volatility and risk, INCR or ALLO?

InterCure has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, Allogene Therapeutics has a beta of 0.31, meaning that its share price is 69% less volatile than the S&P 500.

Is INCR or ALLO more profitable?

InterCure's return on equity of 0.00% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
Allogene Therapeutics	N/A	-52.98%	-41.28%

Does the media refer more to INCR or ALLO?

In the previous week, Allogene Therapeutics had 1 more articles in the media than InterCure. MarketBeat recorded 2 mentions for Allogene Therapeutics and 1 mentions for InterCure. Allogene Therapeutics' average media sentiment score of 0.78 beat InterCure's score of 0.00 indicating that Allogene Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
InterCure	Neutral
Allogene Therapeutics	Positive

Which has stronger valuation and earnings, INCR or ALLO?

InterCure has higher revenue and earnings than Allogene Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$64.55M	N/A	-$18.32M	N/A	N/A
Allogene Therapeutics	$20K	16,514.12	-$257.59M	-$1.23	-1.23

Do analysts rate INCR or ALLO?

Allogene Therapeutics has a consensus target price of $8.44, indicating a potential upside of 459.23%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Allogene Therapeutics is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Allogene Therapeutics	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90

Summary

Allogene Therapeutics beats InterCure on 7 of the 12 factors compared between the two stocks.